Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Sector news Specialty & Advanced Pharmaceuticals
08:42aDJGLAXOSMITHKLINE : Encouraged By Blood-Cancer Drug Study
07:32aDJSANOFI : Receives U.S. FDA Approval for Insulin Injection Admelog
12:56a Monsanto offers cash to U.S. farmers who use controversial chemical
12/11 ASTRAZENECA : GSK's new pharma head on lookout for cancer deals to boost pipelin..
12/11DJSANOFI : Urges Philippines to Lift Dengue Vaccine Suspension -AFP
12/11 Merck raises stakes in lung cancer as rivals close in
12/11DJROCHE : Reports Positive Results From IMmotion151 Kidney Cancer Trial
12/11 ROCHE : Tecentriq cocktail slows kidney cancer progression
12/08 EU regulators to warn Bayer about Monsanto bid
12/08 ALEXION PHARMACEUTICALS : Elliott Management seeks changes at Alexion - NYT
12/08 Wall Street closes higher after payrolls report
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
12/08DJSHIRE : Names John Miller as Interim CFO From Jan. 1
12/08DJTEVA PHARMACEUTICAL INDUSTRIES : May Cut Up to 10,000 Jobs -Bloomberg
12/08DJSHIRE PLC SHIRE PLC : Directorate Change
12/08DJROCHE : Novartis's Italian Heads Risk Trial for Alleged Market Rigging -Reuters
12/08 ROCHE, NOVARTIS' ITALIAN HEADS RISK : sources
12/08DJSANOFI : Signs Agreement to Produce Vaccines in Algeria
12/08 SANOFI : Philippines to seek refund of $59 million from Sanofi amid vaccine risk
12/07 TSX gains in broad rally led by financials, energy stocks
12/07 Comeback in banks, tech lifts euro zone stocks as Steinhoff collapses
12/07 Roche drug cocktail doubles chance of holding lung cancer at bay
12/07 Whitbread jumps after hedge fund Sachem Head declares stake
12/07 Companies prepare for disorderly Brexit as talks stall
12/07DJROCHE : Posts Positive Phase 3 Interim Results in Hemophilia Study
12/07DJROCHE : Reports Positive Results From IMpower150 Lung Cancer Trial
12/07DJROCHE : Immunotherapy Drug Tecentriq Extended Patients' Lives in Study
12/06 Roche to seize leap-frog opportunity in lung cancer
12/06DJROCHE : Avastin Granted Full Approval by FDA to Treat Glioblastoma
12/06 GSK, other drugmakers bet on post-Brexit UK science
12/06DJBAYER : Johnson & Johnson Ordered to Pay $27.8 Million in Xarelto Lawsuit -Reute..
12/06DJCREDIT MARKETS : Tax Bill Benefits Corporate Bonds -- WSJ
12/06 Australian watchdog takes GlaxoSmithKline, Novartis units to court
12/05 BAYER : Jury orders Bayer, Johnson & Johnson to pay $28 million in Xarelto lawsu..
12/05 MERCK : Nestle to buy vitamin maker Atrium Innovations for $2.3 billion
12/05DJNOVO NORDISK A/S : U.S. FDA Approves Novo Nordisk's Diabetes Treatment
12/05 Paul Singer's Elliott takes stake in takeover target Uniper
12/05 European shares slip in cyclical-defensive tug of war
12/05DJRoche's Breast Cancer Drug Herceptin Faces Biosimilar Competition -Cinco Dias
12/04DJSANOFI : Philippines Suspends Troubled Dengue Drug After More Than 730,000 Immun..
12/04 SANOFI : says monitoring outcomes of ongoing dengue vaccination schemes
12/04 SANOFI : Philippines orders probe into Sanofi dengue vaccine for 730,000 childre..
12/04 SANOFI : Philippines orders probe into Sanofi dengue vaccine for 730,000 childre..
12/04DJSANOFI : Philippines Suspends Troubled Dengue Drug After More Than 730,000 Immun..
12/04DJASTRAZENECA : Says Hard Brexit Could Mean $35.5 Million in Extra Annual Costs
12/04 SANOFI : Brazil recommends restrictions on Sanofi dengue vaccine
12/04DJSANOFI : Philippines Suspends Troubled Dengue Drug After More Than 730,000 Immun..
12/04DJSANOFI : Correction to Philippines Suspends Dengue Drug Article
12/04DJSANOFI : Philippines Suspends Troubled Dengue Drug, After More Than 730,000 Immu..
Financials ($)
Sales 2017 27 998 M
EBIT 2017 11 955 M
Net income 2017 7 316 M
Debt 2017 26 790 M
Yield 2017 2,70%
P/E ratio 2017 20,80
P/E ratio 2018 16,40
EV / Sales 2017 6,45x
EV / Sales 2018 5,71x
Capitalization 154 B